Trial Outcomes & Findings for Cook Enforcer Post-Market Study (NCT NCT03552289)

NCT ID: NCT03552289

Last Updated: 2020-10-19

Results Overview

Percentage of lesions requiring adjunctive treatment immediately following the initial treatment with the Enforcer or conventional angioplasty balloon

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

211 participants

Primary outcome timeframe

Immediately following treatment of stenoses of a mature native arteriovenous dialysis access circuit fistula or graft, up to approximately 1 hour

Results posted on

2020-10-19

Participant Flow

Unit of analysis: Lesions

Participant milestones

Participant milestones
Measure
Cook Enforcer Balloon Catheter
The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula. Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter: The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Conventional Angioplasty Balloon Catheters
Commercial available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula. Conventional angioplasty balloon catheters: Commercial available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Overall Study
STARTED
102 120
109 130
Overall Study
COMPLETED
101 119
106 125
Overall Study
NOT COMPLETED
1 1
3 5

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Cook Enforcer Post-Market Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Cook Enforcer Balloon Catheter
n=102 Participants
The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula. Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter: The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Conventional Angioplasty Balloon Catheters
n=109 Participants
Commercial available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula. Conventional angioplasty balloon catheters: Commercial available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Total
n=211 Participants
Total of all reporting groups
Age, Continuous
65.5 years
STANDARD_DEVIATION 12.4 • n=5 Participants
65.5 years
STANDARD_DEVIATION 12.8 • n=7 Participants
65.5 years
STANDARD_DEVIATION 12.6 • n=5 Participants
Sex: Female, Male
Female
43 Participants
n=5 Participants
51 Participants
n=7 Participants
94 Participants
n=5 Participants
Sex: Female, Male
Male
59 Participants
n=5 Participants
58 Participants
n=7 Participants
117 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants
n=5 Participants
15 Participants
n=7 Participants
20 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
97 Participants
n=5 Participants
93 Participants
n=7 Participants
190 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
3 Participants
n=5 Participants
0 Participants
n=7 Participants
3 Participants
n=5 Participants
Race (NIH/OMB)
Asian
2 Participants
n=5 Participants
2 Participants
n=7 Participants
4 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
43 Participants
n=5 Participants
43 Participants
n=7 Participants
86 Participants
n=5 Participants
Race (NIH/OMB)
White
51 Participants
n=5 Participants
57 Participants
n=7 Participants
108 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=5 Participants
7 Participants
n=7 Participants
9 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Immediately following treatment of stenoses of a mature native arteriovenous dialysis access circuit fistula or graft, up to approximately 1 hour

Percentage of lesions requiring adjunctive treatment immediately following the initial treatment with the Enforcer or conventional angioplasty balloon

Outcome measures

Outcome measures
Measure
Cook Enforcer Balloon Catheter
n=120 Lesions
The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula. Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter: The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Conventional Angioplasty Balloon Catheters
n=130 Lesions
Commercial available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula. Conventional angioplasty balloon catheters: Commercial available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Percent of Lesions Requiring Adjunctive Treatment
30 Lesions
26 Lesions

Adverse Events

Cook Enforcer Balloon Catheter

Serious events: 2 serious events
Other events: 24 other events
Deaths: 1 deaths

Conventional Angioplasty Balloon Catheters

Serious events: 1 serious events
Other events: 23 other events
Deaths: 2 deaths

Serious adverse events

Serious adverse events
Measure
Cook Enforcer Balloon Catheter
n=102 participants at risk
The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula. Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter: The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Conventional Angioplasty Balloon Catheters
n=109 participants at risk
Commercial available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula. Conventional angioplasty balloon catheters: Commercial available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Injury, poisoning and procedural complications
Right Femur Fracture after fall
0.98%
1/102 • Number of events 1 • 90 days
0.00%
0/109 • 90 days
Skin and subcutaneous tissue disorders
Diabetic ulcer of lower extremity
0.98%
1/102 • Number of events 1 • 90 days
0.00%
0/109 • 90 days
Injury, poisoning and procedural complications
Head injury s/p fall
0.98%
1/102 • Number of events 1 • 90 days
0.00%
0/109 • 90 days
Infections and infestations
Septic Shock
0.00%
0/102 • 90 days
0.92%
1/109 • Number of events 1 • 90 days

Other adverse events

Other adverse events
Measure
Cook Enforcer Balloon Catheter
n=102 participants at risk
The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula. Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter: The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Conventional Angioplasty Balloon Catheters
n=109 participants at risk
Commercial available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula. Conventional angioplasty balloon catheters: Commercial available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Vascular disorders
Restenosis or occlusion
23.5%
24/102 • Number of events 26 • 90 days
17.4%
19/109 • Number of events 23 • 90 days
Vascular disorders
Thrombosis
2.0%
2/102 • Number of events 3 • 90 days
5.5%
6/109 • Number of events 8 • 90 days

Additional Information

Alan Saunders

Cook Research Incorporated

Phone: 765-463-7537

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place